Top Tech Companies (1,774)
Don't see your company?
Create a company profile
Starting with a best-in-class canine DNA test, Embark is building a powerful platform for scientific discovery that will accelerate advancements in personalized dog care. Embark’s dog DNA test— the most accurate and highest-rated on the market — helps educate pet owners about their dog’s breed, health, and ancestry. By using Embark’s products, customers can fuel new research and help all dogs (and, ultimately, humans) lead longer, healthier lives. Beyond its most recent genetic discoveries, Embark raised $75 million in Series B funding in 2021. Its continued growth will accelerate its ability to offer insights into certain conditions and make new discoveries about health risks, traits, and breeds. Embark is confident it can extend the lives of dogs by three years within the next decade by empowering dog owners with personalized, preventative care for their pets; giving breeders the tools they need to breed healthier dogs; and expanding the company’s research and partnerships to identify the genetic and other causes of healthy aging in dogs. As Embark’s database expands, it will be able to exponentially increase the number of novel discoveries it makes to help dogs live healthier, longer lives.
Scismic is a tech platform built by scientists to help biotechs grow qualified and diverse scientific teams. Our specialized algorithm accurately targets relevant candidates for faster hiring. We are funded by the NIH to reduce bias in candidate evaluation through our gender- and race-blind skills matching technology, so you can hire scientists from all walks of life with the skills you need.
Cybersecurity Evolved. As a worldwide leader in next-generation cybersecurity, Sophos protects nearly 400,000 organizations of all sizes in more than 150 countries from today’s most advanced cyberthreats. Powered by SophosLabs – a global threat intelligence and data science team – Sophos’ cloud-native and AI-enhanced solutions secure endpoints (laptops, servers and mobile devices) and networks against evolving cybercriminal tactics and techniques, including automated and active-adversary breaches, ransomware, malware, exploits, data exfiltration, phishing, and more.
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves.
Monotype brings brands to life through type and technology that consumers engage with every day. The company's rich legacy includes a library that can be traced back hundreds of years, featuring famed typefaces like Helvetica, Futura, Times New Roman and more. Monotype also provides a first-of-its-kind service that makes fonts more accessible for creative professionals to discover, license, and use in our increasingly digital world. We work with the biggest global brands, and with individual creatives, offering a wide set of solutions that make it easier for them to do what they do best: design beautiful brand experiences.
PharmaEssentia Corporation is a rapidly growing biopharmaceutical innovator. We are leveraging deep expertise and proven scientific principles to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one product approved in The United States and a diversifying pipeline. We believe in the potential to improve both health and quality of life for patients with limited options today through the combination of rigorous research and innovative thinking. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today we are listed on the Taipei Exchange (TPEx: 6446) and are expanding our global presence with operations in the U.S., Japan, South Korea and China, along with a world-class biologics production facility in Taichung. See our community guidelines: bit.ly/PECcommunity
Emsi Burning Glass is a labor market analytics firm, using data to drive economic prosperity. We collect and integrate complex labor market data and build user-friendly tools to help you understand employment, economic trends, and training needs for your region. We believe that a skilled, well-prepared workforce drives economic prosperity. We work with clients in higher education, workforce development, economic development, site selection, and talent acquisition.
Interwell Health is a kidney care management company that partners with physicians on their mission to reimagine healthcare – with the expertise, compassion, and vision to set the standard for the industry and help patients live their best lives. For more information about Interwell Health, please visit interwellhealth.com.
For 30 years, Weiss Asset Management has developed proprietary value-based investment strategies designed to deliver high risk-adjusted returns to our investors, who include charitable foundations, pension plans, endowments, hospitals, government entities and private investors. We manage approximately $2.7 billion across hedge funds and institutional accounts. We work collaboratively to solve problems, and to identify undervalued assets through deep fundamental research, statistical analysis and an analytically rigorous approach to decision making. Above all else, we value integrity, uncompromising rationality, creativity and entrepreneurship, and continuous learning and improvement. Our team of over 80 individuals is the engine of our success and we welcome truly exceptional candidates from all backgrounds.
.jpg)
Boston Medical Center, located in Boston’s historic South End, is a private, not-for-profit, 567-bed, academic medical center and the primary teaching affiliate for Boston University School of Medicine. Recognized for its high-quality, nationally ranked and comprehensive medical care for the entire family, patients have access to the most current treatment and advancements at BMC. BMC physicians lead the way in pioneering new therapies that impact the care of patients locally and worldwide. In 2013, BMC made the decision to invest in a four-year campus redesign that includes additions to buildings, upgrades to existing structures, and an expansion of the Emergency Department. Once completed, the redesign will provide clinical workspaces with state-of-the-art facilities and equipment to solve BMC's most pressing care delivery needs. Already complete, the hospital’s Shapiro Center is Boston’s newest outpatient care facility and features a quarter-million square feet of clinic space, key support services, one of the region’s most technologically advanced pharmacies, and a bright, spacious café. Housed in a facility that provides world-class, patient-centered care at every visit, BMC doctors are among the best in their field. Many are recognized annually as “Top Doctors” in their medical and surgical specialties by publications such as U.S. News & World Report and Boston magazine. Boston Medical Center is also the largest safety net hospital in New England and extends into the community as a founding partner of Boston HealthNet, a network of 15 community health centers throughout Boston serving more than a quarter million people annually. No matter whom you meet at BMC, all are committed to providing every patient and family member with the highest quality of care, respect, warmth and compassion.
.jpg)
Care Access is a leading decentralized research organization (DRO) that breaks down traditional barriers in clinical research for patients, sponsors, and physicians. Its innovative model brings decentralized trials, Sites On Demand™, Virtual PIs, and Mobile Sites to previously-unreachable patient populations to expand the impact of clinical research. Supported by top pharmaceutical and biotech partners across 20 different therapeutic areas, Care Access is scaling and globalizing its new model for clinical trial delivery, where more physicians and patients can engage in life-saving research to develop new therapies faster. To find out how Care Access is transforming the future of clinical trials, visit www.careaccess.com or email [email protected].
For more than 40 years, GMO has partnered with a broad range of sophisticated institutions, financial intermediaries, and families to provide the investment expertise they need to meet their goals and fulfill their missions. Investing on behalf of our clients is GMO’s sole focus. Across asset classes and around the world, our investment teams identify and exploit long-term opportunities and develop solutions that both anticipate and respond to client needs. GMO is comprised of a collection of investment teams with focused specialties. All are grounded in a long-term, valuation-based investment philosophy – an approach we believe provides the best risk-adjusted returns. GMO partners with an impressive roster of sophisticated clients worldwide, delivering innovative investment solutions and tailored client service. Our clients benefit from our diverse expertise, intellectual curiosity, and open culture of debate, as well as from our ability and willingness to take advantage of contrarian market opportunities. For important disclosure information please visit: https://www.gmo.com/americas/terms-and-conditions/
OCB Eye Health Services provided patients with medical laser and surgical eye care of the highest quality. In addition to eye examinations, our ophthalmologists provide care in the following specialties: cataract, glaucoma, cornea, diseases of the retina, orbital plastics, pediatrics, LASIK refractive surgery and eye trauma. Our staff of 30 ophthalmologists and 13 optometrists care for over 165,000 patients each year with all categories of eye disorders and visual system diseases. This level of care has earned Ophthalmic Consultants of Boston a national and international reputation for excellence.
Manta Network is a decentralized project that delivers plug-and-play privacy for the entire DeFi stack. Built as a layer-1 protocol, the project leverages zkSNARK to provide algorithmically private on-chain transactions. We are launching on Polkadot as a parachain. Our first offerings will be private payments through MantaPay and private exchanging through MantaSwap.
NOBULL is a footwear, apparel and accessory brand for people who train hard and don't believe in excuses. If you think gimmicks in your shoes make you a better athlete, NOBULL is not for you. NOBULL products perform with you when and where you need them. That's it. Our gear won't make you fitter. The only thing that will make you fitter is you. Working hard. Day after day.
Addgene is a self-sustaining, thriving nonprofit life sciences organization that was created to help scientists share DNA-based research materials called plasmids. Our mission is to accelerate research and discovery by improving access to useful research materials and information. Since its founding in 2004, Addgene has grown and innovated in order to assist the research community by archiving and sharing useful DNA-based research materials and resources (such as plasmids, viral vectors, and recombinant antibodies) with scientists worldwide. Broad availability of these unique research materials promotes the advancement of research in a wide variety of disciplines, including cancer, heart disease, and neurodegenerative disorders, while increasing collaboration within the scientific community. As an “Addgenie”, you will work collaboratively with internal teams to help fulfill this mission, including scientists, software engineers and product developers, renowned customer support teams, scientific content creators, and business development professionals. Together, Addgenies create and enhance opportunities for research scientists to deposit their materials, find products and resources easily on our website, and receive unparalleled support in receiving and expertly using our materials in their own experiments.
Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platform harnesses state-of-the-art engineering, and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T-cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last.
Our passion is helping leading brands make critical decisions with confidence. We are a full-service custom market research and strategy firm. As a Top 50 Market Research firm, we’re known for our relentless business decision focus and cutting-edge creativity. Our passion is helping the world’s leading brands engage, innovate, and grow. Known for our deeply consultative approach and rock-solid execution, we leverage the best of advanced analytics, consumer psychology, and market strategy to tackle game-changing initiatives. THAT’s the CMB Difference!
10Beauty, located in Burlington, MA, is building the definitive Intelligent Beauty company, leveraging robotics and automation to reimagine how people can interact with machines on a service level. We are about to close on a $20M Series B round of funding (total funding of $40M), to launch the world’s first full manicure machine next year, having already pre-sold over $13M in annual manicure pod subscriptions to our first launch partners. Our diverse 30-person and growing team is built around individuals with a consistently demonstrated track record of introducing successful new-to-the-world products (75+ new products launched across the team).
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
